Nilotinib within its licensed indication for the first line treatment of chronic myeloid leukaemia
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 79
- Referral date:
- 01 March 2009
- Topic area
- Cancer
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Communications manager:
- TBC
- Executive Lead:
- Peter Littlejohns
- Project manager:
- TBC
- Technical Lead:
- Joao Vieria
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 6 August 2010 |
Nilotinib for the first line treatment of chronic myeloid leukaemia was referred to NICE as a Single Technology Appraisal (STA). NICE have recently undertaken a draft scope consultation exercise and held a scoping workshop for the proposed appraisal of dasatinib for the first line treatment of chronic myeloid leukaemia. As a result of this work, the Department of Health has now asked NICE to carry out a multiple technology appraisal of dasatinib, nilotinib and standard-dose imatinib within their licensed indications for the first-line treatment of chronic myeloid leukaemia (including part-review of TA70) as part of our 24th wave work programme. Therefore nilotinib will not be appraised through the STA process. |
For further information on our processes and methods, please see our CHTE processes and methods manual